Gene Therapy: Clinical Gains Yield A Wealth Of Research Opportunities

investigation that will carry advances forward The transfer of genetic materials into humans to correct diseases--gene therapy--is a new medical enterprise, barely three years old in the clinic. But in the short time since a research team at the National Institutes of Health in Bethesda, Md., first treated a young girl's genetically compromised immune system with a transfusion of her own DNA-corrected white blood cells on Sept. 14, 1990, gene therapy has grown to command considerable public

Written byFranklin Hoke
| 8 min read

Register for free to listen to this article
Listen with Speechify
0:00
8:00
Share

investigation that will carry advances forward

The transfer of genetic materials into humans to correct diseases--gene therapy--is a new medical enterprise, barely three years old in the clinic. But in the short time since a research team at the National Institutes of Health in Bethesda, Md., first treated a young girl's genetically compromised immune system with a transfusion of her own DNA-corrected white blood cells on Sept. 14, 1990, gene therapy has grown to command considerable public and scientific attention.

While the public focuses on the small but growing number of clinical successes, scientists also predict an exponential growth in multi-disciplinary research opportunities linked to the young field. Disciplines that will be called on to contribute, these researchers say, include virology, immunology, cell biology, pathology, genetics, biochemistry, and molecular biology.

"The fun thing about gene therapy is that it requires a wide variety of skills,"says Richard C. Boucher, director of ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Related Topics

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies